CLEVELAND, March 18, 2020 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that
Ludwig-Maximilians-University Hospital in Munich has begun patient treatments with
MRIdian® Linac, a cutting-edge radiation therapy system that
combines the latest innovations in precision radiation delivery and
ground-breaking MRI-guidance.
The first patient treated at Ludwig-Maximilians-University
Hospital was treated for an ultra-central lung lesion using
stereotactic body radiation therapy (SBRT), which delivers high
doses of radiation to targeted areas in fewer treatment sessions
than conventional radiation therapy. The goal of SBRT is to
irradiate the tumor, mitigate side effects and impact to healthy
surrounding tissue, and provide greater convenience to patients.
Because of MRIdian's continual MRI-guided adaptive capabilities and
automatic beam gating, it is well-suited to deliver SBRT
treatments.
In the first six weeks of MRIdian patient treatments at
Ludwig-Maximilians-University Hospital, other indications treated
with MRIdian included prostate, pancreas, spine and abdominal
lesions. More than 70 percent of the 110 delivered fractions were
delivered using MRIdian's full-online adaptive capabilities, which
enable clinicians to make treatment plan modifications, both
during treatment delivery and throughout the course of
treatment.
"Our MRIdian treatment schedule is filling up quickly, as so
many of our patient cases can benefit from the precision afforded
by MRI-guided and adapted therapy," said Stefanie Corradini, M.D., radiation oncologist
and Chief of Service for the MR-guided radiotherapy program at LMU
Munich. "MRIdian allows us to see and address potential changes in
the size, shape and location of the lesion or surrounding anatomy,
and thereby deliver higher therapeutic doses when appropriate.
These capabilities will significantly benefit our patients who can
now receive a more precise and personalized approach to their
radiation therapy."
Currently 34 MRIdian systems are installed at hospitals around
the world, where they are being used to treat a wide variety of
solid tumors and are the focus of numerous ongoing research
efforts. MRIdian has been the subject of hundreds of peer-reviewed
publications, scientific meeting abstracts and presentations. More
than 8,000 patients have been treated with MRIdian. For a list of
treatment centers, please visit:
https://viewray.com/mridian-locator.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures, and
markets the MRIdian® radiation therapy system. MRIdian is built
upon a proprietary high-definition MR imaging system designed from
the ground up to address the unique challenges and clinical
workflow for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purposely
built to deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Private Securities Litigation
Reform Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, the rate of new orders,
upgrades and installations, ViewRay's financial guidance for the
full year 2020 and ViewRay's conference calls to discuss its fourth
quarter 2019 and year to date results. Actual results could differ
from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the ability
to commercialize MRIdian Linac System, demand for ViewRay's
products, the ability to convert backlog into revenue, and the
timing of delivery of ViewRay's products, the timing, results and
other uncertainties associated with clinical trials, the ability to
raise the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates and overall
market conditions. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to ViewRay's business in general, see ViewRay's current
and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2019 and its
2019 Quarterly Reports on Form 10-Q, as updated periodically with
the company's other filings with the SEC. These forward-looking
statements are made as of the date of this press release, and
ViewRay assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ludwig-maximilians-university-hospital-begins-patient-treatments-with-viewrays-mridian-linac-301025925.html
SOURCE ViewRay, Inc.